Axsome Therapeutics, Inc. (AXSM)
AXSM Price and Sentiment
AXSM Latest news
The average of price targets set by Wall Street analysts indicates a potential upside of 143.7% in Axsome (AXSM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Axsome Therapeutics (AXSM) reports a narrower-than-expected Q3 loss. The company is actively preparing to support the commercial launch of its two under-review candidates, AXS-05 and AXS-07.
Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q3 2021 Results - Earnings Call Transcript
The company provided its third-quarter update.
Company to host conference call today at 8:00 AM Eastern
Let us look at four drug/biotech companies, VTRS, RDUS, AXSM and EDIT, which are gearing up for their earnings release.
Axsome to host conference call and webcast on Monday, November 8, 2021 at 8:00 AM Eastern Time
Last month we discussed that Axsome Therapeutics stock is likely to continue to see higher levels after it rose 6% in a week following the U.S. FDA's acceptance of a new drug application for the company's migraine drug - AXS-07. AXSM stock has since then rallied 27% to levels of nearly $38 now.
$100 million now available upon the potential FDA approval of AXS-05